ReChord: Randomized Trial Of The Neochord DS1000 System Versus Open Surgical Repair

Now Actively Enrolling for the ReChord Trial

 UPMC has been selected as a center for the ReChord trial (Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair). The objective of the ReChord trial is to assess the safety and effectiveness of the Neochord DS1000 System in subjects with moderate to severe degenerative mitral regurgitation receiving mitral valve repair without cardiopulmonary bypass. It will compare outcomes of the Neochord DS1000 system to traditional mitral valve surgery.

Mitral Valve Repair

 The first line treatment of mitral regurgitation, particularly for mitral valve prolapse, is valve repair surgery. The Neochord DS1000 system allows for a beating heart, sternal sparing mitral valve repair using an artificial chordae tendineae. The procedure is done via transapical approach.

Which Patients Are Eligible?

 Potential candidates have the following characteristics:

  1. Indicated for isolated surgical mitral valve repair per ACC/AHA and ESC/EACTS guidelines
  2. Moderate to severe degenerative mitral regurgitation
  3. Suitable anatomy
    1. Isolated prolapse of A2 or P2 segment of mitral valve
    2. Anterior mitral leaflet covers at least 65% of anterior-posterior annular distance
    3. Have not had prior mitral valve surgery

Contact Us

For a full list of inclusions/exclusion criteria or to refer a patient:  

Thomas Gleason, MD, is the principal investigator at UPMC. If you see a patient you believe may qualify, please call UPMC Heart and Vascular Institute at 1-855-UPMC-HVI.